Semagluatide is an injectable drug that was initially used to treat type 2 diabetes but was subsequently approved by the Food and Drug Administration (FDA) in 2021 under the brand name Wegovy to help manage weight loss in the 70% of American adults who are obese or overweight
If you or someone you love has an eating disorder and is considering GLP-1 medication, its essential to speak with a healthcare provider experienced in both eating disorders and metabolic health.
Metabolism & Elimination GLP2 undergoes metabolism through pathways typical of peptide therapeutics: Plasma half-life of approximately 5 days in humans, enabling once-weekly administration Primary metabolic pathways include proteolytic cleavage of the peptide backbone, beta-oxidation of the C20 fatty diacid moiety, and amide hydrolysis Not metabolized via cytochrome P450 enzymes, sulfation, or glucuronidation pathways Low potential for drug-drug interactions mediated through hepatic metabolism or transporter systems The extended half-life represents a key pharmacokinetic advantage, with steady-state accumulation of approximately 1.7-fold enabling consistent therapeutic exposure throughout the dosing interval
Cell Death Dis 17 , 363 (2026)
When microdosing is combined with compounded sourcing, two uncertainties may overlap: Sub-therapeutic dosing without clinical validation Product variability outside manufacturer-controlled standards This does not automatically invalidate compounded medication
A little awareness can go a long way this summer
